Measles-containing-vaccine second-dose (MCV2) immunization coverage in Türkiye
Türkiye: Measles-containing-vaccine second-dose (MCV2) immunization coverage was 91.0% in 2025. ▲ Rising
Measles-containing-vaccine second-dose (MCV2) immunization coverage in Türkiye, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Türkiye recorded 91.0% for measles-containing-vaccine second-dose (mcv2) immunization coverage in 2025.
Compared with earlier readings it is down 3.2% on the previous year and up 5.8% over ten years.
Over the whole period, measles-containing-vaccine second-dose (mcv2) immunization coverage in Türkiye peaked at 98.0% in 2005 and was at its lowest, 0.0%, in 2000.
That places Türkiye 66th out of 194 countries with data for 2025, putting it in the middle of the range.
The long-run direction has been consistently rising across the 26 years of available data.
Measles-containing-vaccine second-dose (MCV2) immunization coverage in Türkiye, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 91.0% | — |
| 2002 | 83.0% | -8.8% |
| 2003 | 97.0% | +16.9% |
| 2004 | 97.0% | +0.0% |
| 2005 | 98.0% | +1.0% |
| 2006 | 84.0% | -14.3% |
| 2007 | 94.0% | +11.9% |
| 2008 | 92.0% | -2.1% |
| 2009 | 88.0% | -4.3% |
| 2010 | 91.0% | +3.4% |
| 2011 | 86.0% | -5.5% |
| 2012 | 85.0% | -1.2% |
| 2013 | 98.0% | +15.3% |
| 2014 | 88.0% | -10.2% |
| 2015 | 86.0% | -2.3% |
| 2016 | 85.0% | -1.2% |
| 2017 | 86.0% | +1.2% |
| 2018 | 87.0% | +1.2% |
| 2019 | 88.0% | +1.1% |
| 2020 | 93.0% | +5.7% |
| 2021 | 93.0% | +0.0% |
| 2022 | 94.0% | +1.1% |
| 2023 | 94.0% | +0.0% |
| 2024 | 94.0% | +0.0% |
| 2025 | 91.0% | -3.2% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 82.4% | 0.0% | 98.0% | 10 |
| 2010s | 88.0% | 85.0% | 98.0% | 10 |
| 2020s | 93.2% | 91.0% | 94.0% | 6 |
Countries ranked near Türkiye
More health data for Türkiye
- Un projection of annual infant deaths, annual growth rate -1.72 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5275 % change on previous year (2090)
- Heat deaths vs projected death rates 1,582 (2090)
- Un projection of annual infant deaths 858 (2100)
- Population ages 65 and above, female, annual growth rate 3.23 % change on previous year (2025)
- Population ages 65 and above, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65 and above, female, per capita 0.0592 units per person (2025)
- Population ages 65 and above, male, annual growth rate 3.21 % change on previous year (2025)
- Population ages 65 and above, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65 and above, male, per capita 0.0465 units per person (2025)
Frequently asked questions
- What is measles-containing-vaccine second-dose (mcv2) immunization coverage in Türkiye?
- Measles-containing-vaccine second-dose (mcv2) immunization coverage in Türkiye was 91.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in Türkiye?
- The highest recorded value was 98.0% in 2005.
- What is the lowest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in Türkiye?
- The lowest recorded value was 0.0% in 2000.
- How does Türkiye rank for measles-containing-vaccine second-dose (mcv2) immunization coverage?
- Türkiye ranks 66th out of 194 countries with data for 2025.
- Is measles-containing-vaccine second-dose (mcv2) immunization coverage rising or falling in Türkiye?
- Over the last ten years it is up 5.8%. The long-run trend across the full record is rising.
- Where does this Türkiye data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Measles-containing-vaccine second-dose (MCV2) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).